Vascular permeabilization by intravenous arachidonate in the rat peritoneal cavity: antagonism by ethamsylate.
The hemostatic agent, ethamsylate, inhibits arachidonic acid metabolism by a mechanism independent of cyclooxygenase activity and blocks carrageenan-induced rat paw edema. Here, ethamsylate was investigated for (i) in vivo actions on the free radical-dependent, permeabilizing responses to arachidonic acid and (ii) its antioxidant potential in vitro. Vascular permeability was equated to the extravasation rate of Evans blue from plasma into the rat peritoneal cavity. Antioxidant potential was investigated by classical in vitro tests for superoxide radicals, hydroxyl radicals (OH(.)), and nitric oxide. Intravenous ethamsylate induced a very important and significant reduction of permeability responses to arachidonate, both when given preventively and cumulatively. Thus, (i) ethamsylate significantly reversed arachidonate-induced permeabilization, even at the lowest dose tested (44+/-5% at 10 mg/kg) and (ii) a maximal reversal (about 70%) was reached between 50 and 200 mg/kg ethamsylate. In contrast, ethamsylate (100 mg/kg) was unable to antagonize the vascular permeabilization induced by serotonin (5-HT). In antioxidant assays, ethamsylate showed scavenging properties against hydroxyl radicals generated by the Fenton reaction (H(2)O(2)/Fe(2+)) even at 0.1 microM (-20+/-3%). OH(.) scavenging by ethamsylate reached 42+/-8% at 10 microM and 57+/-7% at 1 mM and was comparable to that of reference compounds (vitamin E, troxerutin, and mannitol). Conversely, ethamsylate was a poor scavenger of superoxide and nitric oxide radicals. In conclusion, intravenous ethamsylate potently antagonized the peritoneal vascular permeabilization induced by arachidonate, an action likely due to its antioxidant properties, particularly against hydroxyl radical. Such a mechanism can explain previous observations that ethamsylate inhibits carrageenan-induced rat paw edema. Whether it also participates in the hemostatic action of ethamsylate deserves further investigation.
Hannaert
Patrick
P
INSERM U400, Faculté de Médecine, 8 rue du Général Sarrail, Cedex 94010, Créteil, France.
Alvarez-Guerra
Miriam
M
Hider
Hamida
H
Chiavaroli
Carlo
C
Garay
Ricardo P
RP
D000818:Animals; D000975:Antioxidants / Q000737:chemistry / Q000494:pharmacology*; D016718:Arachidonic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002199:Capillary Permeability / Q000187:drug effects* / Q000502:physiology; D004396:Coloring Agents; D004979:Ethamsylate / Q000737:chemistry / Q000494:pharmacology*; D005070:Evans Blue; D005119:Extravasation of Diagnostic and Therapeutic Materials; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives* / Q000494:pharmacology; D017665:Hydroxyl Radical / Q000737:chemistry / Q000378:metabolism; D007275:Injections, Intravenous; D009569:Nitric Oxide / Q000737:chemistry / Q000378:metabolism; D010529:Peritoneal Cavity / Q000473:pathology*; D051381:Rats; D013481:Superoxides / Q000737:chemistry / Q000378:metabolism; D014810:Vitamin E / Q000494:pharmacology
D000975:Antioxidants; D004396:Coloring Agents; D006896:Hydroxyethylrutoside; D013481:Superoxides; D014810:Vitamin E; D004979:Ethamsylate; D016718:Arachidonic Acid; D009569:Nitric Oxide; D017665:Hydroxyl Radical; D005070:Evans Blue; C005865:troxerutin